Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 89

1.

Involvement of 5-HT1A and 5-HT2A Receptors but Not α 2-Adrenoceptors in the Acute Electrophysiological Effects of Cariprazine in the Rat Brain In Vivo.

Herman A, El Mansari M, Adham N, Kiss B, Farkas B, Blier P.

Mol Pharmacol. 2018 Dec;94(6):1363-1370. doi: 10.1124/mol.118.113290. Epub 2018 Oct 15. Erratum in: Mol Pharmacol. 2019 Feb;95(2):235.

PMID:
30322874
2.

The novel atypical antipsychotic cariprazine demonstrates dopamine D2 receptor-dependent partial agonist actions on rat mesencephalic dopamine neuronal activity.

Delcourte S, Ashby CR Jr, Rovera R, Kiss B, Adham N, Farkas B, Haddjeri N.

CNS Neurosci Ther. 2018 Dec;24(12):1129-1139. doi: 10.1111/cns.12867. Epub 2018 May 4.

3.
4.

Correction to: The Effects of Cariprazine and Aripiprazole on PCP-Induced Deficits on Attention Assessed in the 5-Choice Serial Reaction Time Task.

Barnes SA, Young JW, Markou A, Adham N, Gyertyán I, Kiss B.

Psychopharmacology (Berl). 2018 May;235(5):1621. doi: 10.1007/s00213-018-4884-x.

PMID:
29564481
5.

The Effects of Cariprazine and Aripiprazole on PCP-Induced Deficits on Attention Assessed in the 5-Choice Serial Reaction Time Task.

Barnes SA, Young JW, Markou A, Adham N, Gyertyán I, Kiss B.

Psychopharmacology (Berl). 2018 May;235(5):1403-1414. doi: 10.1007/s00213-018-4857-0. Epub 2018 Feb 22. Erratum in: Psychopharmacology (Berl). 2018 Mar 21;:.

6.

Cariprazine Exhibits Anxiolytic and Dopamine D3 Receptor-Dependent Antidepressant Effects in the Chronic Stress Model.

Duric V, Banasr M, Franklin T, Lepack A, Adham N, Kiss B, Gyertyán I, Duman RS.

Int J Neuropsychopharmacol. 2017 Oct 1;20(10):788-796. doi: 10.1093/ijnp/pyx038.

7.

Long-term effects of aripiprazole exposure on monoaminergic and glutamatergic receptor subtypes: comparison with cariprazine.

Choi YK, Adham N, Kiss B, Gyertyán I, Tarazi FI.

CNS Spectr. 2017 Dec;22(6):484-494. doi: 10.1017/S1092852916000894. Epub 2017 Jan 6.

PMID:
28059046
8.

Preferential binding to dopamine D3 over D2 receptors by cariprazine in patients with schizophrenia using PET with the D3/D2 receptor ligand [(11)C]-(+)-PHNO.

Girgis RR, Slifstein M, D'Souza D, Lee Y, Periclou A, Ghahramani P, Laszlovszky I, Durgam S, Adham N, Nabulsi N, Huang Y, Carson RE, Kiss B, Kapás M, Abi-Dargham A, Rakhit A.

Psychopharmacology (Berl). 2016 Oct;233(19-20):3503-12. doi: 10.1007/s00213-016-4382-y. Epub 2016 Aug 15.

9.

The dopamine D₃-preferring D₂/D₃ dopamine receptor partial agonist, cariprazine, reverses behavioural changes in a rat neurodevelopmental model for schizophrenia.

Watson DJG, King MV, Gyertyán I, Kiss B, Adham N, Fone KCF.

Eur Neuropsychopharmacol. 2016 Feb;26(2):208-224. doi: 10.1016/j.euroneuro.2015.12.020. Epub 2015 Dec 11.

PMID:
26723167
10.

Effects of cariprazine, a novel antipsychotic, on cognitive deficit and negative symptoms in a rodent model of schizophrenia symptomatology.

Neill JC, Grayson B, Kiss B, Gyertyán I, Ferguson P, Adham N.

Eur Neuropsychopharmacol. 2016 Jan;26(1):3-14. doi: 10.1016/j.euroneuro.2015.11.016. Epub 2015 Nov 19.

11.

Cariprazine delays ouabain-evoked epileptiform spikes and loss of activity in rat hippocampal slices.

El-Mallakh RS, Payne RS, Schurr A, Gao Y, Lei Z, Kiss B, Gyertyán I, Adham N.

Psychiatry Res. 2015 Sep 30;229(1-2):370-3. doi: 10.1016/j.psychres.2015.05.114. Epub 2015 Jun 27.

PMID:
26160196
12.

Cariprazine exerts antimanic properties and interferes with dopamine D2 receptor β-arrestin interactions.

Gao Y, Peterson S, Masri B, Hougland MT, Adham N, Gyertyán I, Kiss B, Caron MG, El-Mallakh RS.

Pharmacol Res Perspect. 2015 Feb;3(1):e00073. doi: 10.1002/prp2.73. Epub 2014 Dec 2.

13.

Attenuation of anhedonia by cariprazine in the chronic mild stress model of depression.

Papp M, Gruca P, Lasoń-Tyburkiewicz M, Adham N, Kiss B, Gyertyán I.

Behav Pharmacol. 2014 Sep;25(5-6):567-74. doi: 10.1097/FBP.0000000000000070.

PMID:
25083572
14.

Long-term effects of cariprazine exposure on dopamine receptor subtypes.

Choi YK, Adham N, Kiss B, Gyertyán I, Tarazi FI.

CNS Spectr. 2014 Jun;19(3):268-77. doi: 10.1017/S1092852913000680. Epub 2013 Nov 8.

PMID:
24229617
15.

Brain uptake and distribution of the dopamine D3 /D2 receptor partial agonist [11 C]cariprazine: an in vivo positron emission tomography study in nonhuman primates.

Tóth M, Varrone A, Steiger C, Laszlovszky I, Horváth A, Kiss B, Gyertyán I, Adham N, Halldin C, Gulyás B.

Synapse. 2013 May;67(5):258-64. doi: 10.1002/syn.21631. Epub 2013 Feb 8.

PMID:
23238770
16.

Cariprazine, a dopamine D(3)-receptor-preferring partial agonist, blocks phencyclidine-induced impairments of working memory, attention set-shifting, and recognition memory in the mouse.

Zimnisky R, Chang G, Gyertyán I, Kiss B, Adham N, Schmauss C.

Psychopharmacology (Berl). 2013 Mar;226(1):91-100. doi: 10.1007/s00213-012-2896-5. Epub 2012 Oct 19.

17.

Immobilization and stability of lipase from Mucor racemosus NRRL 3631.

Adham NZ, Ahmed HM, Naim N.

J Microbiol Biotechnol. 2010 Feb;20(2):332-9.

18.

Cariprazine (RGH-188), a dopamine D(3) receptor-preferring, D(3)/D(2) dopamine receptor antagonist-partial agonist antipsychotic candidate: in vitro and neurochemical profile.

Kiss B, Horváth A, Némethy Z, Schmidt E, Laszlovszky I, Bugovics G, Fazekas K, Hornok K, Orosz S, Gyertyán I, Agai-Csongor E, Domány G, Tihanyi K, Adham N, Szombathelyi Z.

J Pharmacol Exp Ther. 2010 Apr;333(1):328-40. doi: 10.1124/jpet.109.160432. Epub 2010 Jan 21.

PMID:
20093397
19.

Extracellular lipase of Aspergillus niger NRRL3; production, partial purification and properties.

Adham NZ, Ahmed EM.

Indian J Microbiol. 2009 Mar;49(1):77-83. doi: 10.1007/s12088-009-0004-2. Epub 2009 Apr 21.

20.

Identification and characterization of pseudoirreversible nonpeptide antagonists of the neuropeptide Y Y5 receptor and development of a novel Y5-selective radioligand.

Mullins D, Adham N, Hesk D, Wu Y, Kelly J, Huang Y, Guzzi M, Zhang X, McCombie S, Stamford A, Parker E.

Eur J Pharmacol. 2008 Dec 28;601(1-3):1-7. doi: 10.1016/j.ejphar.2008.10.021. Epub 2008 Oct 18.

PMID:
18976648
21.

Prevalence of low back pain among physical therapists in Kuwait.

Shehab D, Al-Jarallah K, Moussa MA, Adham N.

Med Princ Pract. 2003 Oct-Dec;12(4):224-30.

22.
23.

Trace amines: identification of a family of mammalian G protein-coupled receptors.

Borowsky B, Adham N, Jones KA, Raddatz R, Artymyshyn R, Ogozalek KL, Durkin MM, Lakhlani PP, Bonini JA, Pathirana S, Boyle N, Pu X, Kouranova E, Lichtblau H, Ochoa FY, Branchek TA, Gerald C.

Proc Natl Acad Sci U S A. 2001 Jul 31;98(16):8966-71. Epub 2001 Jul 17.

24.

Identification and characterization of two G protein-coupled receptors for neuropeptide FF.

Bonini JA, Jones KA, Adham N, Forray C, Artymyshyn R, Durkin MM, Smith KE, Tamm JA, Boteju LW, Lakhlani PP, Raddatz R, Yao WJ, Ogozalek KL, Boyle N, Kouranova EV, Quan Y, Vaysse PJ, Wetzel JM, Branchek TA, Gerald C, Borowsky B.

J Biol Chem. 2000 Dec 15;275(50):39324-31.

25.

Identification and characterization of two neuromedin U receptors differentially expressed in peripheral tissues and the central nervous system.

Raddatz R, Wilson AE, Artymyshyn R, Bonini JA, Borowsky B, Boteju LW, Zhou S, Kouranova EV, Nagorny R, Guevarra MS, Dai M, Lerman GS, Vaysse PJ, Branchek TA, Gerald C, Forray C, Adham N.

J Biol Chem. 2000 Oct 20;275(42):32452-9.

26.

N-Methyl-5-tert-butyltryptamine: A novel, highly potent 5-HT1D receptor agonist.

Xu YC, Schaus JM, Walker C, Krushinski J, Adham N, Zgombick JM, Liang SX, Kohlman DT, Audia JE.

J Med Chem. 1999 Feb 11;42(3):526-31.

PMID:
9986723
27.

Functional characterization of the recombinant human 5-hydroxytryptamine7(a) receptor isoform coupled to adenylate cyclase stimulation.

Adham N, Zgombick JM, Bard J, Branchek TA.

J Pharmacol Exp Ther. 1998 Nov;287(2):508-14.

PMID:
9808674
28.

5-HT1F receptor agonists inhibit neurogenic dural inflammation in guinea pigs.

Johnson KW, Schaus JM, Durkin MM, Audia JE, Kaldor SW, Flaugh ME, Adham N, Zgombick JM, Cohen ML, Branchek TA, Phebus LA.

Neuroreport. 1997 Jul 7;8(9-10):2237-40.

PMID:
9243618
29.

[3H]RS 57639, a high affinity, selective 5-HT4 receptor partial agonist, specifically labels guinea-pig striatal and rat cloned (5-HT4S and 5-HT4L) receptors.

Bonhaus DW, Berger J, Adham N, Branchek TA, Hsu SA, Loury DN, Leung E, Wong EH, Clark RD, Eglen RM.

Neuropharmacology. 1997 Apr-May;36(4-5):671-9.

PMID:
9225293
30.

Cloning and characterization of the guinea pig 5-HT1F receptor subtype: a comparison of the pharmacological profile to the human species homolog.

Adham N, Bard JA, Zgombick JM, Durkin MM, Kucharewicz S, Weinshank RL, Branchek TA.

Neuropharmacology. 1997 Apr-May;36(4-5):569-76.

PMID:
9225282
31.

Modeling the G-protein-coupled neuropeptide Y Y1 receptor agonist and antagonist binding sites.

Du P, Salon JA, Tamm JA, Hou C, Cui W, Walker MW, Adham N, Dhanoa DS, Islam I, Vaysse PJ, Dowling B, Shifman Y, Boyle N, Rueger H, Schmidlin T, Yamaguchi Y, Branchek TA, Weinshank RL, Gluchowski C.

Protein Eng. 1997 Feb;10(2):109-17.

PMID:
9089810
32.
33.

[3H]5-hydroxytryptamine labels the agonist high affinity state of the cloned rat 5-HT4 receptor.

Adham N, Gerald C, Schechter L, Vaysse P, Weinshank R, Branchek T.

Eur J Pharmacol. 1996 May 23;304(1-3):231-5.

PMID:
8813606
34.

Metabolic alterations of zinc and prostaglandins in both human and animal colonic tumor cells.

Song MK, Adham NF, Heng MC, Costea NV, Heng MK, Ament ME.

J Am Coll Nutr. 1995 Oct;14(5):473-9.

PMID:
8522726
35.

The 5-HT4 receptor: molecular cloning and pharmacological characterization of two splice variants.

Gerald C, Adham N, Kao HT, Olsen MA, Laz TM, Schechter LE, Bard JA, Vaysse PJ, Hartig PR, Branchek TA, et al.

EMBO J. 1995 Jun 15;14(12):2806-15.

36.

The cloned human 5-HT1E receptor couples to inhibition and activation of adenylyl cyclase via two distinct pathways in transfected BS-C-1 cells.

Adham N, Vaysse PJ, Weinshank RL, Branchek TA.

Neuropharmacology. 1994 Mar-Apr;33(3-4):403-10.

PMID:
7984278
37.

A single point mutation increases the affinity of serotonin 5-HT1D alpha, 5-HT1D beta, 5-HT1E and 5-HT1F receptors for beta-adrenergic antagonists.

Adham N, Tamm JA, Salon JA, Vaysse PJ, Weinshank RL, Branchek TA.

Neuropharmacology. 1994 Mar-Apr;33(3-4):387-91.

PMID:
7984276
38.

Cell-specific coupling of the cloned human 5-HT1F receptor to multiple signal transduction pathways.

Adham N, Borden LA, Schechter LE, Gustafson EL, Cochran TL, Vaysse PJ, Weinshank RL, Branchek TA.

Naunyn Schmiedebergs Arch Pharmacol. 1993 Dec;348(6):566-75.

PMID:
8133900
39.

Cloning of a novel human serotonin receptor (5-HT7) positively linked to adenylate cyclase.

Bard JA, Zgombick J, Adham N, Vaysse P, Branchek TA, Weinshank RL.

J Biol Chem. 1993 Nov 5;268(31):23422-6.

40.

Receptor reserve masks partial agonist activity of drugs in a cloned rat 5-hydroxytryptamine1B receptor expression system.

Adham N, Ellerbrock B, Hartig P, Weinshank RL, Branchek T.

Mol Pharmacol. 1993 Mar;43(3):427-33.

PMID:
8095694
41.

Cloning of another human serotonin receptor (5-HT1F): a fifth 5-HT1 receptor subtype coupled to the inhibition of adenylate cyclase.

Adham N, Kao HT, Schecter LE, Bard J, Olsen M, Urquhart D, Durkin M, Hartig PR, Weinshank RL, Branchek TA.

Proc Natl Acad Sci U S A. 1993 Jan 15;90(2):408-12.

42.

Serotonin receptor subtypes.

Hartig PR, Adham N, Zgombick J, Macchi M, Kao HT, Schechter L, Branchek T, Weinshank R.

Psychopharmacol Ser. 1993;10:15-25. Review. No abstract available.

PMID:
8361973
43.
44.

Acute desensitization of muscarinic receptors in the isolated guinea-pig ileal longitudinal muscle.

Eglen RM, Adham N, Whiting RL.

J Auton Pharmacol. 1992 Jun;12(3):137-48.

PMID:
1629233
45.

Prostaglandin interacts with steroid sex hormones in the regulation of intestinal zinc transport.

Song MK, Kim YY, Heng MC, Adham NF, Ament ME.

Comp Biochem Physiol Comp Physiol. 1992 Mar;101(3):477-81.

PMID:
1348677
46.

The rat 5-hydroxytryptamine1B receptor is the species homologue of the human 5-hydroxytryptamine1D beta receptor.

Adham N, Romanienko P, Hartig P, Weinshank RL, Branchek T.

Mol Pharmacol. 1992 Jan;41(1):1-7.

PMID:
1732716
47.

Molecular cloning and characterization of a high affinity dopamine receptor (D1 beta) and its pseudogene.

Weinshank RL, Adham N, Macchi M, Olsen MA, Branchek TA, Hartig PR.

J Biol Chem. 1991 Nov 25;266(33):22427-35.

48.
49.

Cloning, expression, and pharmacological characterization of a human alpha 2B-adrenergic receptor.

Weinshank RL, Zgombick JM, Macchi M, Adham N, Lichtblau H, Branchek TA, Hartig PR.

Mol Pharmacol. 1990 Nov;38(5):681-8.

PMID:
2172775
50.

The molecular biology of serotonin receptors. An overview.

Hartig P, Kao HT, Macchi M, Adham N, Zgombick J, Weinshank R, Branchek T.

Neuropsychopharmacology. 1990 Oct-Dec;3(5-6):335-47. Review.

PMID:
2078270

Supplemental Content

Support Center